Core Viewpoint - Harmony Biosciences Holdings, Inc. reported strong preliminary, unaudited net product revenue for Q4 and full year 2025, indicating continued growth and profitability in the biotech sector [1] Financial Performance - The company announced Q4 2025 net product revenue of approximately $243 million [1] - Full year 2025 net product revenue reached approximately $868 million [1] - Harmony has achieved six consecutive years of revenue growth, demonstrating a solid financial trajectory [1] Business Strategy - Harmony is on track to extend the pitolisant franchise, which is a key component of its product portfolio [1] - The company is positioning itself as a profitable, self-funding biotech entity with a robust late-stage pipeline [1] - Strong long-term growth prospects are highlighted, reinforcing the company's strategic direction [1]

Core Insights - Harmony Biosciences Holdings, Inc. reported earnings of $239.5 million for Q3 2025, marking a 29% year-over-year revenue growth for WAKIX® [1] - The revenue growth was driven by an increase of approximately 500 in the average number of patients for the quarter, indicating a strong trajectory towards blockbuster status for WAKIX in the treatment of narcolepsy [1] - The company has achieved four consecutive years of revenue growth and profitability, showcasing its strong market position and operational success [1]